AMERICAN HEART JOURNAL, cilt.154, sa.6, 2007 (SCI-Expanded)
Background Patients with diabetes mellitus (DM) are at higher risk for complications after ST-elevation myocardial infarction (STEMI) than patients without DM. Potent antithrombotic therapies may offer particular benefit for these high-risk patients and must be balanced against the potential for increased bleeding.